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Abstract
PURPOSE: Upregulation of Bcl-2 family members is
a well-established mechanism in the development of
androgen-independent prostate cancer. Inhibition of
the antiapoptotic proteins Bcl-2 and Mcl-1 may delay
the transition to androgen-independent growth.EXPERI-
MENTAL DESIGN: We have established a prostate can-
cer model with VCaP prostate cancer cells in vivo to
study the transition to androgen independence. Here,
we investigated the efficacy of AT-101 (R-(–)-gossypol
acetic acid; a pan small molecule inhibitor of Bcl-2,
Bcl-xL, and Mcl-1) in combination with surgical cas-
tration to delay the onset of androgen-independent
growth in vivo.RESULTS:AT-101 (15mg/kg, per os (p.o.)
5 days/week) in combination with surgical castration
delayed the onset of androgen-independent prostate
cancer growth in vivo. In addition, we demonstrate the
induction of caspase-9– and caspase-3–dependent in-
duction of apoptosis following AT-101 treatment in vitro
which was accompanied by an AT-101–induced down-
regulation of Bcl-2 and Mcl-1 mRNA and protein ex-
pression. CONCLUSIONS: We conclude that AT-101 in
combination with surgical castration delays the onset
of androgen-independent prostate cancer in vivo by
disrupting the antiapoptotic activity of Bcl-2 upregu-
lation during the transition to androgen independence.
Further studies are needed to define the mechanism
of action by which AT-101 attenuates the expression
of Bcl-2 and Mcl-1 and to characterize the potential for
AT-101 in combination with hormone therapy.
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Introduction
The primary treatment for patients with metastatic prostate
cancer is androgen deprivation therapy (ADT). The majority
of advanced prostate cancer tumors that recur are initially
responsive to androgen blockade; however, nearly 100% of
patients undergoing ADT will fail hormone therapy and
progress to an androgen-independent phenotype. The cur-
rent paradigm is that androgen-independent growth is due to a
clonal expansion of prostate cancer cells that are able to survive
and proliferate in an androgen-depleted milieu. The role of Bcl-
2 in androgen-independent prostate cancer is well documented
and has been shown to be a prominent mechanism by which
cells adapt to an androgen-independent environment following
ADT [1]. Bcl-2 is an antiapoptotic protein that prevents the
release from mitochondria by sequestering Bax, a proapoptotic
Bcl-2 family member protein. Bcl-2 was originally identified in
Burkitt lymphoma as a result of a chromosome translocation
t(14;18) prevalent in B cells [2]. The Bcl-2 family of proteins
now includes both proapoptotic (i.e., Bax, Bak, Bok [Mtd], Bad,
Bid, Bim, Bik, Hrk, Bcl-Xs, APR [Noxa], p193, Bcl-G, Nip3, and
Nix [BNIP]) and antiapoptotic (i.e., Bcl-2, Bcl-xL, Bcl-W, MCL-1,
Bfl-1 [A1], BOO [Diva], and NR-13) proteins [3]. The ratios and
interactions of anti- and proapoptotic Bcl-2 family proteins are
known to be intimately involved in the sensitivity or resistance
of cells to apoptotic stimuli. Alterations in the amounts of these
proteins have been associated with a variety of pathologic
conditions, including cancer [4]. Specifically, proapoptotic mem-
bers (e.g., Bax) homodimerize when released from the mito-
chondrial membrane and induce a loss in membrane potential of
the mitochondria leading to cytochromeC release. Antiapoptotic
members (e.g., Bcl-2) heterodimerize with proapoptotic mem-
bers and prevent the loss in mitochondrial membrane potential
and release of cytochrome C.
AT-101 (R-()-gossypol acetic acid) is a polyphenolic com-
pound isolated from cottonseeds; it inhibits Bcl-2 by acting as a
BH3 mimetic and disrupts the heterodimerization of Bcl-2 with
proapoptotic family members. AT-101 was found to mimic the
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proapoptosis proteins and is able to bind to the BH3 domains
of Bcl-2, Mcl-1, and Bcl-xL [5]. AT-101 has been shown to be
therapeutically active as a single agent in several mouse
models including breast, prostate, colon, and non–small cell
lung cancer [6–9]. Here, we demonstrate that AT-101 ad-
ministration delays the onset of androgen-independent pros-
tate cancer in vivo. Recently, VCaP prostate cancer cells
have been shown to express the wild-type androgen receptor
(AR) and, as xenografts, develop an androgen-independent
phenotype following castration in mice [10]. Previously, we
demonstrated that Bcl-2 expression in VCaP androgen–
independent cells was significantly upregulated in compari-
son to VCaP androgen–dependent cells [10]. The use of AT-
101 along with ADT may provide a means to increase the
time between remission and reoccurrence of androgen-
dependant prostate cancer.
Materials and Methods
Materials
AT-101 was kindly provided by Ascenta Therapeutics (San
Diego, CA). Dihydrotestosterone (DHT) was purchased from
Sigma-Aldrich (St. Louis, MO) and WST-1 and the Cell Death
Detection ELISA were purchased from Roche Inc. (Basel,
Switzerland). Anti–Bcl-2, anti–Mcl-1, anti–Bcl-xL, anti-Bak,
anti-Bad, anti-Bax, anti–caspase-9, anti–caspase-3, anti–
caspase-7, anti–caspase-6, anti–poly(ADP-ribose) polymer-
ase (PARP), anti-AR, and anti–b-actin were purchased from
Cell Signaling Technology (Danvers, MA).
Cell Culture
VCaP cells were obtained from a lumbar vertebral meta-
static lesion through the Rapid Autopsy program at the
University of Michigan [6]. Cells were cultured in Dulbecco’s
modified Eagle’s medium supplemented with 10% fetal bo-
vine serum and 1% antibiotic/antimicotic and incubated at
37jC. PC-3 prostate cancer cells were obtained from the
American Type Culture Corporation (Manassas, VA) and main-
tained in RPMI supplemented with 10% fetal bovine serum
and 1% antibiotic/antimicotic.
Proliferation Assay
VCaP cells were seeded at a density of 8  104 cells/well
in a 96-well plate with complete media, whereas PC-3 cells
were seeded at a density of 1  104 cells/well in a 96-well
plate also with complete media. The plates were then in-
cubated for 24 hours and then treated for 72 hours. WST-1
was added to each well at a 1:10 concentration, incubated for
2 hours then read in a microplate reader (VersaMax Tunable;
Molecular Devices, Sunnyvale, CA) at 440 nm.
Western Blot
Treated cells were lysed in RIPA buffer (120 mM NaCl,
50 mM Tris, pH 7.6, 0.05% NP-40, 1 mM EGTA, 1 mg/ml leu-
peptin, 1 mg/ml aprotinin, 1 mM PMSF, 1 mM NaVO3, 1 mg/ml
pepstatin, and 1 mg/ml okadaic acid). Lysates were resolved
using sodium dodecyl sulfate–polyacrylamide gel elec-
trophoresis and then transferred to polyvinylidene difluo-
ride membrane (Millipore, Billerica, MA). Membranes were
blocked using 5% milk in TBS + 0.5% Tween for 1 hour at
room temperature. The membranes were then incubated in
primary antibody either overnight at 4jC or for 90 minutes at
room temperature. They were then washed three times in
TBS + 0.5% Tween then incubated for 60 minutes in HRP-
conjugated secondary antibody (Cell Signaling). Presence
of the proteins was determined using Immobilon Western
Chemiluminescent HRP Substrate (Millipore).
Cell Death Detection ELISA
VCaP cells were seeded at a density of 8  104 cells/well
in a 96-well plate with complete Dulbecco’s modified Eagle’s
medium, whereas PC-3 cells were seeded at a density of 1
104 cells/well in a 96-well plate with complete RPMI. The
plates were incubated for 24 hours and then treated for
72 hours. After incubation, the cells were lysed and the
ELISA was conducted according the protocol supplied by
the manufacturer (Roche).
Subcutaneous Injection of VCaP Cells
Xenograft tumors were established as previously de-
scribed [10]. Briefly, male severe combined immunodefi-
ciency disease (SCID) mice (5–6 weeks) were injected
subcutaneously with 1  106 VCaP prostate cancer cells
in 200 ml of Matrigel (BD Biosciences, Inc., San Jose, CA).
Tumor volumeswere calculated by calipermeasurement per-
formed weekly to monitor and track tumor growth (tumor vol-
ume = L  W  W  0.56). Once tumor volumes reached
250 mm3, mice were allotted into groups as follows: 1) intact,
2) AT-101-only (15 mg/kg, per os (p.o.), 5 days/week), 3) cas-
tration, and 4) castration + AT-101 (15 mg/kg, p.o., 5 days/
week). AT-101 treatment was initiated 24 hours postsurgery.
Preparation of AT-101
A 0.5% carboxymethylcellulose stock was prepared to
be used in the oral administration of the drug. A polytron
homogenizer (Biospec Products, Bartlesville, OK) was used
for 10 seconds to completely dissolve 1.0 g of carboxy-
methylcellulose in 200 ml of purified water. This solution
was stored at 4jC for up to 1 month. The drug was prepared
weekly and kept refrigerated for no longer than 7 days. Mice
were fed 100 ml daily, of 0.375 mg/ml AT-101 homogenized
in carboxymethylcellulose.
Quantitative Polymerase Chain Reaction (QPCR) Assay
VCaP cells were cultured to 80% confluence. Total RNA
was isolated from cell lines using a reagent (Trizol; Invitrogen
Corp, Carlsbad, CA) following the manufacturer’s specifi-
cations. Purified RNA (5 mg) was converted to cDNA using
Super Script II reverse transcriptase (Invitrogen) following
the manufacturer’s instructions and used for gene expres-
sion analysis by real-time polymerase chain reaction (PCR)
using a thermocycler (ABI Prism 7900HT). Primers and probes
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were purchased from Applied Biosystems, Inc. (Foster City,
CA) and used with TaqMan Universal PCR Master Mix,
No AmpErase UNG. Glyceraldehyde 3-phosphate dehydro-
genase (GAPDH) was used as an internal control to normalize
and compare each sample. Cycle conditions for real-time PCR
were 95jC (15 seconds), 60jC (1 minute), and 72jC (1 min-
ute) for 40 cycles. Threshold cycle number for each sample
was normalized to GAPDH for that sample and expressed on
a log scale relative to GAPDH expression.
Statistical Analysis
Data were analyzed with GraphPad Prism software (San
Diego, CA). A one-way analysis of variance was used with
Bonferroni’s post hoc analysis for comparison betweenmulti-
ple groups. Student’s t test was used for comparison be-
tween two groups. Significance was defined as a P value
of < .05.
Results
Expression of the Bcl-2 Family Members in Androgen
Sensitive versus Androgen Independent VCaP
Prostate Cancer Cells
To determine the mechanism mitigating the transition to
androgen-independent prostate cancer, we assessed the
expression profile of the Bcl-2 family by QPCR and com-
pared the parental VCaP androgen-sensitive prostate can-
cer line to a daughter VCaP androgen-independent prostate
cancer line. VCaP cells were implanted subcutaneously in
male SCID mice and tumor growth was monitored by caliper
measurement. To induce the androgen-independent pheno-
type, mice were surgically castrated or left intact when the
tumors reached 250 mm3 as previously described [10]. Tu-
mors were collected once they reached the 1000-mm3 critical
mass and Bcl-2 family member expression was analyzed.
Analysis revealed a significant upregulation of Bcl-2, Bcl-xL,
Bcl-W, and Mcl-1 (antiapoptotic) in the VCaP tumors from
castrated mice compared to VCaP tumors from intact mice
(Figure 1). In addition, there was a significant downregu-
lation of Bax, Bak, and Bad (proapoptotic) in the VCaP tu-
mors from castrated mice compared to VCaP tumors from
intact mice (Figure 1). No significant change in expression of
Bid, Bim, Puma, Noxa, CIAP-2, CIAP-1, ML-IAP, and survivin
was observed.
AT-101 in Combination with Surgical Castration Attenuates
Androgen-Independent Growth of Prostate Cancer
We next evaluated the efficacy of inhibiting the related
antiapoptotic Bcl-2 family members that were upregulated
following surgical castration. AT-101 inhibits Bcl-2 family pro-
teins by binding to their BH3 domains and disrupts the
heterodimerization of Bcl-2, Bcl-xL, Bcl-W, and Mcl-1 with
proapoptotic members of the Bcl-2 family at submicromolar
affinity [11,12]. In vivo administration of AT-101 (15 mg/kg,
p.o., 5 days/week) as a single agent in intact mice signifi-
cantly reduced the development of VCaP tumor growth com-
pared to untreated tumors at weeks 2 to 6 (P < .001 and
each week by unpaired t test) (Figure 2). No difference was
seen between the AT-101-only and castration-only groups;
however, AT-101 in combination with surgical castration
delayed the onset of androgen-independent VCaP tumor
growth compared to castration-only or AT-101–only groups
in vivo (castration vs castration + AT-101: week 4, P = .0012;
week 5, P = .172; week 6, P = .0245) (Figure 2). Tumor
xenografts were isolated for histology when the tumors
reached f 1000 mm3. Expression of Bcl-2 and the AR
were visualized by immunohistochemistry analysis (Figure 2,
B– I). By qualitative analysis, AR expression was upregulated
in the castration group compared to the intact group but the
AR expression was localized to the cytoplasm (Figure 2, B
and C). AT-101-only had no effect on AR expression com-
pared to the intact group (Figure 2, B and D). Combination of
AT-101 with surgical castration maintained the upregulation
Figure 1. Upregulation of proapoptotic Bcl-2 family members in androgen-independent VCaP prostate cancer cells. Differential Bcl-2 family mRNA expression was
determined by quantitative real-time PCR in androgen-sensitive VCaP cells (VCaP AS) and androgen-independent VCaP cells (VCaP AI). mRNA expression was
determined and normalized to GAPDH levels using the DCT method. Samples were run in triplicate in each of three independent experiments (mean ± SD, *P < .01).
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of AR; however, AR became localized primarily to the nu-
cleus compared to the castration-only group (Figure 2, C and
E). Similarly, Bcl-2 expression was upregulated on surgical
castration (Figure 2, F and G) and this upregulation was at-
tenuated by AT-101 treatment in combination with castra-
tion (Figure 2, G and I ).
AT-101 Induces Apoptosis Through Activation of
Caspase-9, -3, and -7 in VCaP Cells
To determine the efficacy of AT-101 antitumor activity in
VCaP cells directly, we assessed the effects of AT-101 on
VCaP cell viability and apoptosis in vitro. VCaP parental cell
viability was assessed using the WST-1 cell viability assay as
previously described [10]. VCaP cells were treated with in-
creasing concentrations of AT-101 (1–10 mM) and cell viability
was measured at 72 hours posttreatment (Figure 3A). Treat-
ment with AT-101 (1–10 mM) resulted in a dose-dependent
decrease in VCaP cell viability after 72 hours compared to
the vehicle control (VCaP cells: vehicle, 1.034 ± 0.45; AT-101
1 mM, 0.707 ± 0.019; AT-101 5 mM, 0.491 ± 0.015; AT-101
Figure 2. In vivo administration of AT-101 in combination with surgical cas-
tration delays the onset of androgen-independent prostate cancer. (A) VCaP
cells were implanted subcutaneously in male SCID mice and tumor growth
monitored by weekly caliper measurements. Mice were surgically castrated
or left intact when tumors reached 200 mm3 and AT-101 (15 mg/kg, p.o.
5 days/week) was administered by gavage 24 hours postcastration [intact
(gray line), castrate (solid line, E), AT-101 (dashed line, 5), and AT-101 +
castration (dashed line,D)]. (B– I) Tumor sections were analyzed for AR and
Bcl-2 expression by immunohistochemistry.
Figure 3. AT-101 induces apoptosis in vitro. (A) Effects of AT-101 [0–10 M]
for 72 hours was determined on VCaP (open bars) and PC-3 cells (closed
bars). Data are presented as mean ± SD from four independent experiments
(*P < .05, **P < .001). (B) Treatment of VCaP cells with AT-101 [0–10 M] for
72 hours resulted in a dose-dependent increase in apoptosis as detected by
ELISA. Data are presented as mean ± SD from three independent experi-
ments (*P < .05, **P < .01). (C) AT-101 [5 M] induced caspase-9, -3, and -7
activation and PARP cleavage as detected by immunoblot analysis. Cells
were treated with AT-101 [5 M] for 24, 48, or 72 hours and duplicate sam-
ples for each treatment are representatives of four independent experiments.
-Actin was used as a loading control for each sample.
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10 mM, 0.410 ± 0.01; mean ± SD, *P < .05 and **P < .001).
Furthermore, we compared the antitumor activity of AT-101
on VCaP cell viability to PC-3 cell viability and found that
VCaP cells are more sensitive to AT-101 in vitro (PC-3 cells:
vehicle, 1.250 ± 0.099; AT-101 1 mM, 1.238 ± 0.037; AT-101
5 mM, 0.92 ± 0.04; AT-101 10 mM, 0.368 ± 0.005; mean ± SD,
*P < .05 and **P < .01). To determine if the mechanisms of
AT-101 on VCaP viability/proliferation were due to induction of
apoptosis, VCaP cells were treated with increasing concen-
trations of AT-101 (1–10 mM) and apoptosis was quantified
using the Cell Death Detection ELISA (Roche) which mea-
sures histone-complexed DNA fragments released from cells
undergoing apoptosis (Figure 3B). Treatment with AT-101
(1–10 mM) resulted in a dose-dependent increase in VCaP
cell apoptosis after 72 hours compared to the vehicle con-
trol (VCaP cells: vehicle, 0.66 ± 0.41; AT-101 1 mM, 1.064 ±
0.9; AT-101 5 mM, 1.615 ± 0.18; AT-101 10 mM, 1.985 ± 0.11;
mean ± SD, *P < .05 and **P < .01). Activation of apoptosis
in VCaP cells by AT-101 was assessed by immunoblot analy-
sis for caspase activation. Treatment of VCaP cells with
AT-101 (5 mM) induced activation of caspase-9, -3, and -7
and cleavage of PARP (Figure 3C).
AT-101 Decreases Bcl-2 and Mcl-1 Expression in VCaP
Cells In Vitro
To further determine the mechanism of AT-101–induced
apoptosis in vitro, VCaP cells were treated with increas-
ing concentrations of AT-101 (1–10 mM) for 24, 48, and
72 hours. Bcl-2 and Mcl-1 expression was determined by
immunoblot analysis and revealed that AT-101 treatment of
VCaP cells resulted in a dose-dependent downregulation
of Bcl-2 expression at 24, 48, and 72 hours (Figure 4A). In
addition, Mcl-1 expression was similarly downregulated at
24, 48, and 72 hours with AT-101 at 5 and 10 mM. The dose-
dependent downregulation of Bcl-2 and Mcl-1 in response to
AT-101 treatment was confirmed by QPCR (Figure 4B).
Inhibition of AT-101–Induced Apoptosis By DHT
Next, the ability of AR activation with DHT to attenuate
AT-101–mediated apoptosis in VCaP cell in vitro was de-
termined. Stimulation of VCaP cells placed in androgen-
depleted media with AT-101 (5 mM) for 72 hours resulted
in an induction of apoptosis compared to vehicle-treated
control cells (Figure 5A). The presence of DHT (100 nM)
significantly attenuated the AT-101–mediated induction of
apoptosis (vehicle, 0.261 ± 0.14; AT-101 5 mM, 1.529 ± 0.45;
DHT 100 nM, 0.58 ± 0.18; AT-101 5 mM + DHT 100 nM,
0.631 ± 0.12; mean ± SD, *P < .001 and **P < .01). In
contrast, the presence of DHT did not have an effect on
AT-101–mediated apoptosis in PC-3 cells placed in andro-
gen-depleted media (vehicle, 0.222 ± 0.02; AT-101 5 mM,
0.93 ± 0.05; DHT 100 nM, 0.277 ± 0.013; AT-101 5 mM+DHT
100 nM, 0.924 ± 0.01; mean ± SD, *P < .05) (Figure 5B). Sim-
ilar effects of DHT (100 nM) on AT-101–mediated apoptosis
Figure 4. AT-101 downregulates Bcl-2 and Mcl-1 in VCaP cells. (A) The effects of AT-101 on Bcl-2 and Mcl-1 protein expression were determined by immunoblot
analysis. VCaP cells were treated with AT-101 [1–10 M] for 24, 48, or 72 hours and compared to DMSO vehicle-treated cells (control). Data are representative of
three independent experiments and -actin was used as a loading control. (B and C) AT-101– induced decrease in Bcl-2 and Mcl-1 expression was confirmed
by QPCR. VCaP cells were treated with AT-101 [1–10 M] for 24 (–5– ), 48 ( –o– ), or 72 (–E– ) hours before quantitative analysis of Bcl-2 and Mcl-1 mRNA
expression. Data were normalized to GAPDH levels and graphed as a percent of DMSO vehicle-treated levels.
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in VCaP cells placed in androgen-depleted media was ob-
served when caspase-3 activation was assessed by immuno-
blot analysis (Figure 5C), although DHT did not inhibit the
AT-101–induced decrease in Bcl-2 or Mcl-1 expression in
VCaP or PC-3 cells (Figure 5D).
Kinetics of Bcl-2 Expression in VCaP Prostate Cancer
Cells Following Surgical Castration
The kinetics of castration on Bcl-2 expression was as-
sessed by immunoblot analysis. Animals harboring a VCaP
subcutaneous tumor underwent surgical castration as de-
scribed above. Tumors were collected at various time points
(0, 4, and 12 hours and 1, 2, 3, 5, 7, 10, and 14 days post-
castration). Bcl-2 expression was significantly upregulated
as early as 4 hours postcastration and remained significantly
elevated (Figure 6).
Discussion
Bcl-2 family proteins are overexpressed in many cancers
and have been proposed as therapeutic targets in non–
Hodgkin’s lymphoma (Bcl-2), myeloma (Mcl-1), chronic lym-
phocytic leukemia (Bcl-2 and Mcl-1), prostate cancer (Bcl-xL
and Bcl-2), melanoma (Bcl-2), and other cancers. Prosur-
vival proteins products of Bcl-2, Bcl-xL, Mcl-1, and Bcl-W
may contribute to cancer cell pathogenesis and resistance to
cytotoxic therapy by binding to BH3 domains of proapoptotic
family members, sequestering them and inhibiting their abil-
ity to promote cell death. Previously, we have demonstrated
the upregulation of Bcl-2 expression in VCaP prostate can-
cer cells in vivo following surgical castration as a mechanism
of progression to androgen independence [10]. In this study,
we demonstrate that administration of AT-101, a small mol-
ecule inhibitor of proapoptotic members of the Bcl-2 family,
delays the onset of androgen-independent growth of VCaP
prostate cancer xenografts in vivo. Administration of AT-101
attenuated the upregulation of Bcl-2 on castration and pre-
vented the enhanced prosurvival advantage of elevated
Bcl-2 levels. In vitro AT-101–induced apoptosis through the
activation of caspase-9, which is consistent with the activa-
tion of the mitochondrial death pathway. The mechanism of
Bcl-2–mediated antiapoptosis is through binding to proapop-
totic proteins (Bax, Bak, and Bad) and inhibiting their acti-
vation of the mitochondrial death pathway by compromising
Figure 5. DHT rescues AT-101– induced apoptosis in VCaP cells in vitro. VCaP (A) and PC-3 (B) cells were grown in androgen-depleted media and treated with
AT-101 [5 M] for 72 hours in the presence or absence of DHT (100 nM). Apoptosis was measured by ELISA and data are presented as the mean ± SD from three
independent experiments (*P < .001). (C) The effects of DHT (100 nm) on AT-101 [5 M] for 72 hours on caspase-3 activation was assessed by immunoblot
analysis. 1, DMSO vehicle control; 2, AT-101 (5 M, 72 hours); 3, DHT (100 nM, 72 hours); 4, AT-101 (5 M) + DHT (100 nM). (D) The effects of DHT (100 nm) on
AT-101 [5 M] for 72 hours on Bcl-2, Mcl-1, Bcl-xL, Bak, Bad, and Bax was assessed by immunoblot analysis. 1, DMSO vehicle control; 2, – AT-101 (5 M,
72 hours); 3, DHT (100 nM, 72 hours); 4, AT-101 (5 M) + DHT (100 nM).
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the mitochondrial membrane integrity releasing cytochrome
C and thus activating caspase-9 cleavage.
The transition to androgen-independent prostate cancer
is a tremendous hurdle to overcome for the treatment of
prostate cancer. Multiple mechanisms have been identified
that contribute to the transition to the androgen-independent
phenotype [13–17]. Receptor tyrosine kinases become ac-
tivated and the AR is phosphorylated producing a ligand-
independent AR [18]. Other growth factors and hormones
have been shown to induce AR activation and transloca-
tion to the nucleus [18,19]. In this study we demonstrate
that upregulation of Bcl-2 is an important mechanism by
which VCaP prostate cancer cells transition to androgen in-
dependence in vivo following surgical castration. Interest-
ingly, Bcl-2 expression was significantly upregulated within
4 hours following surgical castration and maintained an ele-
vated expression status up to 14 days postcastration. These
data suggest that administration of AT-101 may be more
appropriately administered before castration (hormonal ma-
nipulation) to achieve a greater efficacy in preventing up-
regulation of Bcl-2 and thereby further delaying the onset
of androgen-independent disease. Recently, AT-101 was
tested in 23 men with hormone refractory prostate can-
cer who progressed following hormonal therapy but who
had not yet received systemic chemotherapy [20]. Prelimi-
nary evidence of AT-101 activity in this population was dem-
onstrated, as three (15%) patients met the criteria for a
prostate-specific antigen (PSA) response (e.g., z 50% de-
cline in PSA), with two (10%) patients having a confirmed
response. Of 12 (47.8%) patients who had measurable
disease, 53.8% had radiographically stable disease follow-
ing AT-101 monotherapy. These data indicate that AT-101
has biologic activity as a single agent in hormone refractory
prostate cancer as demonstrated by declines in PSA slope
and PSA partial responses per the Bubley criteria. The ac-
tivity of AT-101 in this population of patients is being explored
further in an ongoing Phase 1/2 trial of AT-101 in combina-
tion with docetaxel and prednisone. An additional trial of
AT-101 in combination with anti–androgen therapy in men
with untreated D2 prostate cancer is also planned. In con-
clusion, in this study, AT-101–mediated inhibition of Bcl-2
and Mcl-1 has proven to be efficacious in delaying the onset
of androgen-independent prostate cancer using the VCaP
prostate cancer model as previously described [10]. Further
studies are needed to understand the mechanisms involved
in AT-101 downregulation of Bcl-2 and Mcl-1 as well as to
identify the most effective time of AT-101 delivery around
hormonal therapy.
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